We have located links that may give you full text access.
Clinical evaluation of the relationship between systemic disease and the time of onset of peri-implantitis: a retrospective cohort study.
Journal of Oral Implantology 2022 July 27
The role of systemic diseases in the development and progression of peri-implantitis remains unclear and requires discussion from various perspectives. This retrospective cohort study aimed to evaluate whether the types of systemic diseases affecting the time of onset of peri-implantitis. The cohort consisted of patients who underwent maintenance implant treatment between January 1998 and June 2020. Information on age, sex, history of periodontal disease, smoking habits, body mass index (BMI), systemic diseases, implant placement sites, and diagnosis of peri-implantitis were extracted. The relationships between the time of onset of peri-implantitis and the medical history of systemic diseases were determined statistically by applying the Kaplan-Meier analysis method and log-rank test. A total of 216 implants in 89 patients (34 male and 55 female) were included in this study. The average patient age was 53.9 ± 11.8 years at the first visit, and the mean duration of maintenance was 7 years and 4 months. A total of 43 patients had medical histories and were assigned to the systemic disease group. In this group, the overall prevalence of peri-implantitis was 25.4% (29 of 114 implants). The medical history of systemic diseases (odds ratio [OR] 6.87, 95% confidence interval [CI] 2.37-19.9) and dental history of periodontitis (OR 3.64, 95% CI 1.25-10.6) were assessed as risk factors for peri-implantitis. A significant difference in the time of onset of peri-implantitis was confirmed between patients with systemic disease and healthy patients. Dabetes mellitus, osteoporosis, and hypertension had a significant impact on the earlier onset of peri-implantitis.
Full text links
Related Resources
Trending Papers
Advances in Clinical Cardiology 2023: A Summary of Key Clinical Trials.Advances in Therapy 2024 May 15
Nutrition in the intensive care unit: from the acute phase to beyond.Intensive Care Medicine 2024 May 22
The Therapy and Management of Heart Failure with Preserved Ejection Fraction: New Insights on Treatment.Cardiac Failure Review 2024
Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.Cochrane Database of Systematic Reviews 2024 May 22
Bronchiectasis management in adults: state of the art and future directions.European Respiratory Journal 2024 May 24
Drug Therapy for Acute and Chronic Heart Failure with Preserved Ejection Fraction with Hypertension: A State-of-the-Art Review.American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 2024 April 5
Pathophysiological Link and Treatment Implication of Heart Failure and Preserved Ejection Fraction in Patients with Chronic Kidney Disease.Biomedicines 2024 April 31
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app